Charles M Rudin Selected Research

Lipase (Acid Lipase)

1/2020	Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
1/2017	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles M Rudin Research Topics

Disease

151	Neoplasms (Cancer) 04/2024 - 01/2002
66	Lung Neoplasms (Lung Cancer) 03/2024 - 09/2009
57	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2024 - 03/2004
50	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 05/2002
25	Adenocarcinoma of Lung 11/2023 - 04/2013
16	Disease Progression 12/2023 - 02/2003
11	Neoplasm Metastasis (Metastasis) 12/2023 - 11/2013
10	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 10/2014
8	Carcinogenesis 01/2021 - 11/2005
8	Medulloblastoma 04/2015 - 09/2009
7	Neutropenia 04/2024 - 04/2002
7	Thrombocytopenia (Thrombopenia) 11/2023 - 11/2004
7	Basal Cell Carcinoma (Rodent Ulcer) 06/2015 - 09/2009
6	Adenocarcinoma 01/2023 - 01/2015
5	Brain Neoplasms (Brain Tumor) 04/2024 - 03/2006
5	Hypersensitivity (Allergy) 01/2021 - 11/2004
5	Fatigue 01/2020 - 02/2006
4	Diarrhea 04/2024 - 03/2008
3	Radiation Pneumonitis 05/2024 - 10/2002
3	Anemia 04/2024 - 03/2011
3	Small Cell Carcinoma 01/2023 - 01/2019
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 08/2015
3	Pleural Effusion (Pleural Effusions) 12/2021 - 02/2003
3	Carcinoma (Carcinomatosis) 01/2020 - 01/2017
3	Nausea 05/2015 - 03/2011
2	Leukopenia 04/2024 - 05/2015
2	Breast Neoplasms (Breast Cancer) 12/2023 - 03/2023
2	Microsatellite Instability 10/2023 - 12/2019
2	Neuroendocrine Carcinoma 01/2023 - 01/2017

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 01/2024 - 02/2006
18	Biomarkers (Surrogate Marker)IBA 05/2024 - 03/2011
17	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2018
14	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 03/2004
11	LigandsIBA 01/2024 - 01/2012
10	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 10/2002
10	Cisplatin (Platino)FDA LinkGeneric 01/2024 - 05/2002
10	RNA (Ribonucleic Acid)IBA 10/2023 - 03/2011
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2013
10	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2008
10	HhAntag691IBA 08/2016 - 09/2009
9	PlatinumIBA 11/2023 - 01/2005
8	Transcription Factors (Transcription Factor)IBA 04/2024 - 09/2017
8	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 10/2006
7	Cell-Free Nucleic AcidsIBA 04/2024 - 11/2019
7	Phosphotransferases (Kinase)IBA 01/2021 - 03/2008
7	ErbB Receptors (EGF Receptor)IBA 12/2019 - 03/2008
6	Irinotecan (Camptosar)FDA LinkGeneric 04/2024 - 04/2004
6	osimertinibIBA 01/2023 - 01/2018
6	Circulating Tumor DNAIBA 11/2022 - 01/2017
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 03/2008
6	Docetaxel (Taxotere)FDA Link 10/2015 - 05/2002
6	Antisense OligonucleotidesIBA 02/2008 - 04/2002
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 05/2013
5	Peptides (Polypeptides)IBA 01/2020 - 03/2011
4	NucleotidesIBA 03/2024 - 01/2022
4	atezolizumabIBA 02/2024 - 09/2017
4	B7-H1 AntigenIBA 11/2023 - 03/2017
4	pembrolizumabIBA 01/2023 - 01/2020
4	Messenger RNA (mRNA)IBA 01/2022 - 11/2009
4	ChromatinIBA 01/2022 - 11/2009
4	Gemcitabine FDA Link 01/2020 - 05/2002
4	CrizotinibIBA 01/2020 - 06/2011
4	rovalpituzumab tesirineIBA 12/2019 - 08/2015
4	Itraconazole (Sporanox)FDA LinkGeneric 05/2013 - 10/2011
3	Topotecan (Hycamtin)FDA LinkGeneric 04/2024 - 11/2010
3	Glutamine (L-Glutamine)FDA Link 03/2024 - 11/2020
3	AntioxidantsIBA 03/2024 - 06/2005
3	entinostat (MS 275)IBA 11/2023 - 12/2011
3	Histone Deacetylase InhibitorsIBA 11/2023 - 09/2013
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2023 - 07/2014
3	delta proteinIBA 01/2023 - 01/2017
3	MethyltransferasesIBA 01/2022 - 05/2013
3	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2019
3	Silicon Dioxide (Silica)FDA LinkGeneric 01/2022 - 01/2020
3	EnzymesIBA 01/2021 - 01/2017
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018 - 01/2017
3	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 03/2006
3	CarcinogensIBA 09/2017 - 09/2009
3	Monoclonal AntibodiesIBA 03/2017 - 02/2009
3	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2017 - 06/2013
3	Azacitidine (5 Azacytidine)FDA Link 01/2015 - 12/2011
3	navitoclaxIBA 05/2014 - 03/2011
3	ABT-737IBA 05/2014 - 04/2008
3	SmokeIBA 09/2012 - 09/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2009 - 02/2003
2	nintedanibIBA 05/2024 - 01/2023
2	ProdrugsIBA 03/2024 - 01/2019
2	Radioisotopes (Radionuclides)IBA 01/2024 - 01/2021
2	Glycoproteins (Glycoprotein)IBA 01/2024 - 04/2011
2	GlutaminaseIBA 11/2023 - 11/2017
2	AntigensIBA 07/2023 - 06/2012
2	Neutralizing AntibodiesIBA 07/2023 - 02/2011
2	Neoplasm Antigens (Tumor Antigens)IBA 05/2023 - 01/2021
2	selinexorIBA 01/2023 - 01/2022

Therapy/Procedure

105	Therapeutics 03/2024 - 01/2002
28	Drug Therapy (Chemotherapy) 01/2024 - 02/2003
17	Immunotherapy 12/2023 - 01/2015
10	Radiotherapy 05/2024 - 10/2002
3	Radioimmunotherapy 01/2022 - 01/2021
2	Castration 01/2023 - 01/2022